No Data
HKEX News | Euconvis Bio-B (01477) rose more than 6%, completed an important strategic cooperation with Alcon, and the company's commercialization progress is smooth.
Euconvision Biotechnology-B (01477) rose more than 6%. As of press time, it rose by 5.83% to HKD 6.35, with a turnover of HKD 10.5044 million.
Hong Kong stock announcement Nuggets | 361 Degrees released mid-term performance, shareholders should account for a surplus of 790 million yuan, an increase of 12.2% year-on-year, with an interim dividend of 16.5 Hong Kong cents per share.
Ocuvis Biosciences-B (01477) plans to acquire assets and introduce products from the global leading ophthalmic company Alcon...
Selected Announcement of Grong Hui (HK Stock) | Ke Holdings-W (02423.HK) net income in the second quarter of the year increased significantly by 46.2%. Buyback authorization increased to 3 billion US dollars.
Today's Focus: Ke Holdings (02423.HK) second quarter net profit increased significantly by 46.2%, and buyback authorization increased to $3 billion. Ke Holdings (02423.HK) announced that in the second quarter of 2024, the company's total trading volume was RMB 839 billion ($115.5 billion), a year-on-year increase of 7.5%. The total trading volume of existing home transactions was RMB 570.7 billion ($78.5 billion), a year-on-year increase of 25.0%. The total trading volume of home decoration and furnishings was RMB 4.2 billion ($0.6 billion), a year-on-year increase of 22.3%. The total trading volume of emerging businesses and others
Express News | Ocumension Acquires Rights to Alcon Eye Drops in Exchange for a 16.7% Equity Stake, Signaling the Commencement of Comprehensive Strategic Relationship
Press Release: Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights
Eucon and Alcon have initiated a comprehensive strategic cooperation. Eucon will have the rights to 8 Alcon products for dry eye conditions in China, while Alcon will hold a 16.7% stake in Eucon.
Shanghai, China – On August 13, 2024, Ocumension Therapeutics (referred to as "Ocumension") announced an agreement with Alcon Inc. (referred to as "Alcon", together with Ocumension referred to as the "Parties"), whereby Ocumension will gain the rights to Alcon's portfolio of 8 dry eye treatment and surgical eye drop products in China, including 7 mature products that are already on the market and one product that is in clinical development stage. The agreement will also cover the areas of research and development, manufacturing and commercialization in China. In connection with the transfer of these rights, Ocumension will issue 139,159,664 shares to Alcon.
Companies Like Ocumension Therapeutics (HKG:1477) Are In A Position To Invest In GrowthNo Data
